

## Ontorpcept

<b>Cat. No.:</b>	HY-P99777
<b>CAS No.:</b>	2131089-46-6
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ontorpcept (TTI-621) is a soluble fusion protein that consists of the human SIRP $\alpha$ N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpcept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpcept is a CD47-blocking checkpoint inhibitor with antitumor activity <sup>[1]</sup> .								
<b>In Vitro</b>	Ontorpcept (0.001-1000 nmol/L; 2 h) dose-dependently increases macrophage phagocytosis of tumor cells with an average EC <sub>50</sub> of 10 nmol/L in primary samples from patients with AML, MDS, multiple myeloma, B-ALL, and T-ALL <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
<b>In Vivo</b>	<p>Ontorpcept (8 mg/kg; i.p., 3 times a week for 4 weeks) shows antitumor effects in NOD. SCID mice with AML xenografts<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>NOD.SCID mice with AML cell transplants<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>8 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 8 mg/kg, 3 times a week for 4 weeks</td> </tr> <tr> <td>Result:</td> <td>Significantly reduced the tumor growth in bone marrow and spleen.</td> </tr> </table>	Animal Model:	NOD.SCID mice with AML cell transplants <sup>[1]</sup>	Dosage:	8 mg/kg	Administration:	Intraperitoneal injection; 8 mg/kg, 3 times a week for 4 weeks	Result:	Significantly reduced the tumor growth in bone marrow and spleen.
Animal Model:	NOD.SCID mice with AML cell transplants <sup>[1]</sup>								
Dosage:	8 mg/kg								
Administration:	Intraperitoneal injection; 8 mg/kg, 3 times a week for 4 weeks								
Result:	Significantly reduced the tumor growth in bone marrow and spleen.								

### REFERENCES

[1]. Petrova PS, et al. TTI-621 (SIRP $\alpha$ Fc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017 Feb 15;23(4):1068-1079.

[2]. Petrova PS, et al. TTI-621 (SIRP $\alpha$ Fc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017 Feb 15;23(4):1068-1079.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA